


Bruce Ling, PhD  
Stanford University School of Medicine  
Department of Surgery

Dear Bruce,

We are writing a letter of support on behalf of your project to deploy an in silico diagnostic model for Kawasaki disease in Russia through contacts at Moscow University. The in silico model combined with new smart phone application would improve diagnosis rates for this serious disease and improve patient health. We understand that you are partnering with Jane Burns at University of California, San Diego, who is a world-renowned Kawasaki Disease researcher. We have great confidence that your experience developing novel diagnostics, combined with her experience in Kawasaki Disease, will provide the project the best possible chance to have a positive clinical impact for patients.

As you know, the SPARK Translational Research program at Stanford University School of Medicine was founded in 2007. Since then, we have supported over 80 drug and diagnostic development projects with a small amount of funding (on average \$50,000/year for two years), educational resources, and targeted mentorship. Projects must address an unmet medical using a novel approach (no “me too” drugs), and we consider any clinical indication. Of the forty-nine graduated programs, >50% have been licensed or entered clinical study after SPARK “de-risking” (18 licenses, additional 11 in clinical study). One of SPARK’s greatest assets is our dedicated cadre of volunteer advisors from biotech, pharma, regulatory and investment industries. A selection committee comprised of academic and industry advisors selected your team to participate in SPARK year 8 to develop a biomarker-based diagnostic for Kawasaki Disease. SPARK has pledged \$50,000 USD over the next year to support this project. The SPARK advisors will also fully support this project with free consulting on a range of diagnostic development topics.

Sincerely,



Daria Mochly-Rosen



Kevin Grimes